Henoch Schonlein purpura nephritis
Conditions
Interventions
Control group:Conventional therapy
Sponsors
Daping Hospital, Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Voluntary participation and signed informed consent; 2. Unlimited gender, age >= 18 years; 3. The pathology of renal biopsy was Henoch Schonlein purpura nephritis; 4. Urinary protein quantification: 0.3-3.5 g/d; 5. Serum albumin > 30 g/L; 6. Glomerular filtration rate (GFR) was > 30 mL/min/1.73m2; 7. Be able to follow the research or follow-up process.
Exclusion criteria
Exclusion criteria: 1. Women who have recently planned to have a baby, are pregnant or are breastfeeding; 2. Inability to understand the potential risks and benefits of the study and to follow up and evaluate as required; 3. No capacity for civil conduct; 4. History of drug or alcohol abuse; 5. There are active infected persons; 6. Complicated with other major organ vasculitis manifestations, such as gastrointestinal bleeding, severe abdominal pain, pulmonary hemorrhage, cerebral hemorrhage, etc.; 7. Patients with other diseases such as diabetic nephropathy, immune diseases, connective tissue diseases, amyloidosis, and those requiring immunosuppressive therapy; 8. The pathological findings of renal biopsy showed that the crescent body was >20% or combined with cellulose-like necrosis; 9. Patients with known renal artery stenosis; 10. Fundus screening for patients with eye diseases who are not suitable to use hydroxychloroquine sulfate; 11. Any more complex medical problems that may interfere with the conduct of research or lead to increased risk, such as malignancies, diseases of the blood system, heart disease, liver disease, AIDS, viral hepatitis, etc.; 12. Patients who have participated in or are participating in other drug clinical trials within 1 month prior to participating in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary protein change rate;24 h urinary protein;Urinary microalbumin/urinary creatinine; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum creatinine;Estimated glomerular filtration rate, eGFR;Urine routine red blood cell count;Remission rate of complications;Recurrence rate;Adverse event rate; | — |
Countries
China
Contacts
Public ContactDai Huanzi
Army Medical University
Outcome results
None listed